Search This Blog

468x60.

728x90

 


Propst AM, Bates GW, Jr. Evaluation and treatment of anovulatory and unexplained infertility. Obstet Gynecol

Clin North Am. 2012;39:507–519.

US Preventive Services Task Force. Folic acid for the prevention of neural tube defects: US Preventive Services

Task Force recommendation statement. Ann Intern Med. 2009;150(9):626–631.

Dombrowski MP et al. ACOG Practice Bulletin No. 90. Asthma in pregnancy. Obstet Gynecol. 2008;111(2):457–

464.

Practice Committee of the American Society for Reproductive Medicine. Multiple gestation associated with

infertility: an American Society for Reproductive Medicine Practice Committee opinion. Fertil Steril.

2012;97(4):825–834.

Facts and Comparisons eAnswers. http://online.factsandcomparisons.com/index.aspx? Accessed June 14,

2017.

Von Hofe J, Bates GW. Ovulation induction. Obstet Gynecol Clin North Am. 2015;42:27–37.

Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile

women. Fertil Steril. 2013;100(2):341–348.

The ESHRE Capri Workshop Group. Intrauterine insemination. Hum Reprod Update. 2009;15(3):265–277.

American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Aromatase inhibitors in

gynecologic practice. Obstet Gynecol. 2008;112:405–407.

Liu A et al. Letrozole versus clomiphene citrate for unexplained infertility: a systematic review and meta-analysis.

J Obstet Gynaecol Res. 2014;40(5):1205–1216.

Tulandi T et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole

or clomiphene citrate. Fertil Steril. 2006;85(6):1761–1765.

Zegers-Hochschild F et al. The International Committee for Monitoring Assisted Reproductive Technology

(ICMART) and the World Health Organization (WHO) revised glossary on ART terminology, 2009. Hum

Reprod. 2009;24(11):2683–2687.

Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted

Reproductive Technology. 2012 Assisted Reproductive Technology: National Summary Report. Atlanta, GA:

US Department of Health and Human Services; 2014.

Practice Committee of the American Society for Reproductive Medicine. Role of tubal surgery in the era of

assisted reproductive technology: a committee opinion. Fertil Steril. 2015;103(6):e37–e43.

Chebab M et al. On-label and off-label drugs used in the treatment of male infertility. Fertil Steril.

2015;103(3):595–604.

Showell MG et al. Antioxidants for male subfertility. Cochrane Database Syst Rev. 2014;(12):CD007411.

American Society for Reproductive Medicine. ART Step by Step Guide. http://www.sart.org/patients/apatients-guide-to-assisted-reproductive-technology/general-information/art-step-by-step-guide/.

Accessed June 14, 2017.

Huirne JAF et al. Contemporary pharmacological manipulation in assisted reproduction. Drugs. 2004;64(3):297–

322.

Albuquerque LE et al. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for

pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev. 2013;(1):CD002808.

Wong JM et al. Efficacy of nafarelin in assisted reproductive technology: a meta-analysis. Hum Reprod Update.

2001;7(1):92–101.

Synarel (nafarelin acetate) [package insert]. New York, NY: Pfizer; 2012.

Nardo LG et al. Controlled ovarian hyperstimulation regimens: a review of the available evidence for clinical

practice. Produced on behalf of the BFS Policy and Practice Committee. Hum Fertil. 2013;16(3):144–150.

Xiao J et al. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian

responders undergoing IVF: a systematic review and meta-analysis. PLoS One. 2014;9(9):e106854.

Al-Shawaf T et al. Safety of drugs used in assisted reproduction techniques. Drug Saf. 2005;28(6):513–528.

Practice Committee of the American Society for Reproductive Medicine. Gonadotropin preparations: past,

present, and future perspectives. Fertil Steril. 2008;90(Suppl 3):S13–S20.

Jee BC et al. Clinical efficacy of highly purified hMG versus recombinant FSH in IVF/ICSI cycles: a metaanalysis. Gynecol Obstet Invest. 2010;70:132–137.

Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome.

Fertil Steril. 2008;90(Suppl 3):S188–S193.

Casper RF. Basic understanding of gonadotropin-releasing hormone-agonist triggering. Fertil Steril.

2015;103(4):867–869.

Humaidan P et al. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril.

2010;94(2):389–400.

Practice Committee of the American Society for Reproductive Medicine. Current clinical irrelevance of luteal

phase deficiency: a committee opinion. Fertil Steril. 2015;103(4):e27–e32.

Mesen TB, Young SL. Progesterone and the luteal phase. Obstet Gynecol Clin North Am. 2015;42:135–151.

Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for

Reproductive Endocrinology and Infertility. Progesterone supplementation during the luteal phase and in early

pregnancy in the treatment of infertility: an educational bulletin. Fertil Steril. 2008;90(Suppl 3):S150–S153.

Practice Committee of the American Society for Reproductive Medicine and the Practice Committee of the

Society for Assisted Reproductive Technology. Criteria for number of embryos to transfer. Fertil Steril.

2013;99(1):44–46.

Wong KM et al. Cryopreservation of human embryos and its contribution to in vitro fertilization success rates.

Fertil Steril. 2014;102(1):19–26.

Society for Assisted Reproductive Technology. Frequently asked questions.

http://www.sart.org/SART_Frequent_Questions/. Accessed June 14, 2017.

Burns LH. Psychiatric aspects of infertility and infertility treatments. Psychiatr Clin North Am. 2007;30:689–716.

Verhaak CM et al. A longitudinal, prospective study on emotional adjustment before, during and after consecutive

fertility treatment cycles. Hum Reprod. 2005;20(8):2253–2260.

Peterson B et al. An introduction to infertility counseling: a guide for mental health and medical professionals. J

Assist Reprod Genet. 2012;29:243–248.

p. 966

The timing and quality of prenatal care can influence an infant’s health

and survival. Early comprehensive care can promote healthier

pregnancies through early detection of risk factors, disease state

management, and encouragement of healthy behaviors.

Case 49-1 (Questions 1, 2)

Important physiologic changes occur in almost all maternal organs during

pregnancy to support the growth and development of the fetus.

Case 49-1 (Question 4)

Drug use during pregnancy presents a significant challenge to clinicians

because of the potential adverse effect on the embryo, fetus, and

newborn. A thorough assessment, including knowledge of the

teratogenic potential of the drug, the critical period of exposure, and

magnitude of risk, must be compared with the background risk.

Case 49-1 (Question 5)

Gastrointestinal (GI) disturbances such as nausea and vomiting and

gastric reflux that occur during pregnancy are common. Treatments

include intravenous (IV) hydration, pyridoxine (vitamin B6

),

antihistamines, and antiemetics for nausea and vomiting. Calcium

carbonate, H2

-receptor antagonists, and proton-pump inhibitors may be

used for common complaints from reflux.

Case 49-1 (Questions 6-10)

Urinary tract infections can frequently occur during pregnancy and can

easily be treated with nitrofurantoin, cephalexin, or penicillin if cultures

are sensitive.

Case 49-1 (Questions 11)

Diabetes mellitus is the most common maternal medical complication

during pregnancy. Tight glycemic control can minimize neonatal and

fetal morbidity and mortality associated with diabetic embryopathy.

Case 49-2 (Questions 1–4),

Case 49-3 (Questions 1, 2),

Case 49-4 (Questions 1–4)

Women with pregnancy-associated hypertension can be grouped into the

following categories: chronic hypertension, preeclampsia–eclampsia,

preeclampsia superimposed on chronic hypertension, and gestational

hypertension.

Case 49-5 (Questions 1–13)

The induction of labor involves the artificialstimulation of uterine

contractions that lead to labor and delivery.

Case 49-6 (Questions 1–5)

Premature birth is the leading cause of neonatal mortality (infant death

<1 month of age). Tocolytic therapy to stop contractions, corticosteroids

Case 49-7 (Questions 1–7)

for fetal lung maturity, and antibiotics for preterm premature rupture of

membranes can help to prolong the pregnancy.

Infectious complications, including bacterial vaginosis and urinary tract

infections, can lead to preterm labor. Chorioamnionitis, an infection of

the chorion and amnion usually diagnosed during labor with elevations in

temperature, should be treated with IV antibiotics until delivery. Human

immunodeficiency virus (HIV)-infected mothers should receive IV

zidovudine and continue their antiretroviral regimens during labor.

Case 49-7 (Questions 8–11),

Case 49-8 (Questions 1, 2)

Obstetric postpartum hemorrhage is one of the top three causes of

maternal mortality in the United States. Pharmacologic therapy for

uterine atony includes oxytocin, methylergonovine, carboprost,

misoprostol, and dinoprostone.

Case 49-8 (Questions 3, 4)

p. 967

p. 968

Alloimmunization occurs when an Rh D-negative mother becomes

immunized after exposure to fetal erythrocytes that carry the D antigen.

Rho

(D) immune globulin should be given to all mothers who are Rh D

negative at 28 weeks’ gestation.

Case 49-9 (Questions 1–5)

LACTATION AND DRUGS IN BREAST MILK

Breast milk is recognized as the optimalsource of nutrition for infants,

with documented benefits not only to infants but also to mothers,

families, and societies, and breast-feeding should be encouraged if

possible.

Case 49-10 (Questions 1, 2),

Case 49-11 (Question 1)

Most drugs are excreted in the breast milk. The pharmacologic and

adverse effects on the infant will be determined by the extent of oral

bioavailability, distribution, metabolism, and rate of elimination. A milkto-plasma ratio can be used to estimate the drug concentration in milk.

The relative infant dose (RID) can be calculated to estimate the infant’s

exposure based on volume of milk ingested.

Case 49-8 (Question 2),

Case 49-12 (Question 1),

Case 49-13 (Question 1)

PREGNANCY

Definitions

PARITY AND GRAVIDA

Parity and gravida are terms used to describe a pregnant woman. Parity is the number

of deliveries after 20 weeks’ gestation. Parity is independent of the number of fetuses

delivered (live or stillborn, single fetus, or twins) or the method of delivery. Gravida

refers to the number of pregnancies a woman has had regardless of the outcome. For

example, a woman who is currently pregnant and has previously delivered one set of

twins and had two spontaneous abortions is described as a gravida 4, para 1 (G4,

P1).

TRIMESTERS OF PREGNANCY

The average pregnancy is approximately 40 weeks when calculated from the first day

of the LMP. Pregnancy is typically divided into three trimesters, approximately 13 to

14 weeks each.

1 The first trimester includes the critical period of organogenesis, the

time in which most of the vital organs are developing, which occurs between weeks

5 and 10. The time between the end of the 20th week of gestation and the end of the

28th day after birth is considered the perinatal period.

DELIVERY

Depending on the gestational age at the time of delivery, the result can be an abortion,

preterm, term, or post-term birth. An abortion is a delivery before 20 weeks’

gestation. A term infant is a fetus delivered between 37 and 42 weeks’ gestation. A

preterm birth is one occurring between 20 and 37 weeks’ gestation, and a post-term

(postmaturity) birth occurs after the beginning of 42 weeks’ gestation. Parturition

refers to labor, and the puerperium is the 6 to 8 weeks after delivery.

Preconceptional Care

CASE 49-1

QUESTION 1: S.C. is a 29-year-old, G1, P1 woman who is interested in becoming pregnant. Her past

medical history is significant for hypothyroidism. She currently is taking levothyroxine 88 mcg by mouth daily.

Provide appropriate counseling to S.C. with regard to preconceptional care.

It is estimated that 3.9 million live births were registered in the United States in

2013, with an estimated 70.8% of women beginning prenatal care in the first

trimester. This can be contributed to several statewide initiatives to increase

education and access to prenatal care.

2 Although much improved, prenatal care is

still not easily accessible to all women. Early comprehensive care can promote

healthier pregnancies through early detection of risk factors, disease state

management, and encouragement of healthy behaviors, and will help to ensure normal

fetal organogenesis. Appropriate preconception counseling and treatment of women

with preexisting high-risk medical conditions, such as diabetes, hypertension, and

epilepsy, can greatly improve pregnancy outcomes. In 2013, the mortality rate in the

United States (from birth through the first year of life) for infants of mothers

beginning prenatal care in the first trimester was 5.96/1,000 live births.

3

S.C. should see her primary-care provider for regular physical examinations and

evaluation of her thyroid function before becoming pregnant. Her first prenatal visit

should generally occur by 8 weeks’ gestational age when she becomes pregnant.

4

Vitamins and Mineral Supplementation

CASE 49-1, QUESTION 2: S.C. asks you to recommend vitamin and mineral supplementation and to provide

guidance on when should she begin taking these vitamins and minerals.

A balanced diet that provides S.C. with multiple B vitamins, oil-soluble vitamins

(A, E, D, and K), folic acid, and minerals (iron, calcium, phosphorus, magnesium,

iodine, zinc) should be encouraged. S.C. should be started on a prenatal multivitamin

if she has not yet started taking one. Prenatal vitamins should be taken months before

conception to ensure that proper nutritional requirements are met during critical

periods of organogenesis and fetal growth.

IRON REQUIREMENTS

Iron requirements increase during pregnancy because of maternal blood volume

expansion, fetal needs, placenta and cord needs, and blood loss at the time of

delivery.

5 Maternal iron deficiency can cause anemia during infancy, spontaneous

abortion, premature delivery, and delivery of a low-birth-weight infant, and is

associated with low neonatal iron stores.

5,6

A woman needs about 18 to 21 mg of iron/day during pregnancy; the body

compensates by increasing iron absorption from the GI tract by about 15% to 50%.

5

The average diet of women

p. 968

p. 969

in the United States does not meet these requirements because only about 6 mg of

iron is absorbed from 1,000 kcal of food. In addition, some women may already have

inadequate body stores of iron before pregnancy. For these reasons, the Centers for

Disease Control and Prevention recommends screening for iron deficiency in

pregnancy in addition to universal iron supplementation except when genetic

conditions such as hemochromatosis are present.

7 Prenatal vitamins usually contain

30 to 60 mg of elemental iron. Women with iron deficiency anemia should be given

60 to 120 mg of elemental iron daily. Iron deficiency anemia during pregnancy

generally is associated with a hemoglobin and hematocrit less than 11 mg/dL and less

than 33%, respectively, during the first and third trimesters or less than 10.5 mg/dL

and less than 32%, respectively, during the second trimester. The classic

morphologic changes observed in the erythrocytes in iron deficiency outside of

pregnancy, hypochromia, and microcytosis are not prominent in pregnant women.

Serum ferritin, however, is low, which has the highest sensitivity and specificity for

diagnosing iron deficiency.

6 S.C.’s hemoglobin and hematocrit should be assessed

now and again at 26 to 28 weeks’ gestation. If her hemoglobin and hematocrit are

normal, the amount of iron in her prenatal vitamin should be sufficient.

FOLATE REQUIREMENTS

Folic acid is essential in the synthesis of DNA and RNA. Pregnant women who take

0.4 to 0.8 mg of folic acid daily during the first trimester of pregnancy are

significantly less likely to have a child with neural tube defects (NTDs), such as

spina bifida and anencephaly.

8,9 NTD can lead to stillbirth, neonatal death, or serious

disabilities. Approximately 4,000 pregnancies in the United States are affected by

NTD each year.

9

NTDs develop within the first month of pregnancy at a time when many women are

unaware of their pregnancy.

9,10

In 1992, the US Public Health Service recommended

that all women with childbearing potential should consume 0.4 mg/day of folic acid

to reduce the risk of an NTD-affected pregnancy.

11

It may be difficult to meet the recommended daily allowance (RDA) for folic acid

because foods contain only a small amount of this vitamin; overcooking and highfiber diets also can reduce the amount of available folic acid from food. Most

prenatal vitamins contain 0.8 to 1 mg of folic acid.

Folic acid supplementation is especially important in women with a history of

infants born with NTD. Women who have had an NTD-affected pregnancy should

receive genetic counseling because they have a 2% to 3% risk of having another such

outcome. Women with previous NTD-affected pregnancies who plan another

pregnancy should take 4 mg/day of folic acid at least 1 month before conception and

through the first 3 months of pregnancy.

11

Women who require 4 mg/day of folic acid should be prescribed folic acid tablets

as an addition to combination prenatal multivitamins (which contain folic acid),

rather than just increasing the number of multivitamin tablets. When several fixedcombination multivitamin tablets are taken daily, the mother could be exposed to a

potentially teratogenic dose of vitamin A. High doses of folic acid do not prevent

NTD better than 0.4 mg/day in women without a previous history of NTD-affected

pregnancies and may complicate the diagnosis of a vitamin B12 deficiency.

9

S.C. should be counseled about the risks for NTD, and given she has no history of

NTD, she should receive adequate folic acid during the remainder of her pregnancy

from a daily prenatal vitamin.

CALCIUM REQUIREMENTS

Calcium is needed during pregnancy for adequate mineralization of the fetal skeleton

and teeth, especially during the third trimester when teeth are formed and skeletal

growth is greatest. The RDA for calcium during pregnancy is 1,000 mg/day for

women of 19 years and older, and 1,300 mg/day for teenagers younger than the age of

19.

12 Large maternal stores can provide calcium if dietary intake is inadequate;

however, depleting maternal stores may put S.C. at risk for osteoporosis later in life.

Foods rich in calcium (e.g., milk, cheese, yogurt, legumes, nuts, dried fruits) or

calcium supplements can be used to meet the calcium RDA.

Commercially Available Home Pregnancy Tests

CASE 49-1, QUESTION 3: S.C starts her prenatal vitamins that contain iron and folic acid immediately. Two

months have passed, and now S.C. believes that she may be pregnant because per period is a couple of weeks

late. She requests your assistance in selecting an over-the-counter commercially available home pregnancy test.

How do these home pregnancy tests work and how should S.C. be counseled?

Commercially available home pregnancy tests are enzyme immunoassays with

monoclonal or polyclonal antibodies that bind to hCG in the urine.

13 hCG is detected

in the maternal circulation and urine approximately 8 to 10 days after conception.

14

Concentrations in the urine closely parallel those in the maternal blood. The hCG

serum concentrations increase rapidly, doubling every 2 days. Peak concentrations

are achieved at 60 to 70 days of pregnancy. Thereafter, hCG concentrations decline

and reach a low by approximately 120 days, at which point concentrations are

maintained for the remainder of the pregnancy.

14

hCG is composed of an α- and a β-subunit. The α-subunit is identical to the αsubunit of other pituitary hormones (e.g., follicle-stimulating hormone, luteinizing

hormone, thyroid-stimulating hormone); however, the β-subunit is specific to hCG.

Pregnancy tests specific for this β-subunit are useful diagnostic tests for confirming

pregnancy.

1 They can provide accurate results within 1 to 2 weeks after ovulation.

1,13

Several kits are available. The tests can be performed privately and quickly and are

easily interpreted. The results are obtained rapidly—within 1 and 5 minutes—and

are highly accurate when performed at the start of the first missed menstrual period.

Although home pregnancy tests are reportedly 98% to 100% accurate when used

correctly, consumer studies have documented accuracy rates as low as 50% to 75%

if product directions are not precisely followed.

13 Many home pregnancy tests

include a second test, which should be repeated at a specified time after the first

negative test result.

S.C. should purchase a product containing two tests and follow the instructions

carefully. If the first test result is negative, S.C. should repeat the test in 1 week if she

has not started menstruating. False-negative results occur when testing is done before

the first day of a missed period or if the urine is not at room temperature.

13 Falsenegative results can also occur with an ectopic (outside the uterus) pregnancy or in

women with ovarian cysts and in those receiving menotropins or chorionic

gonadotropin.

13 False-positive pregnancy test results are rare, but can occur with

serum testing if the woman has circulating heterophilic antibodies directed against

the animal-derived antigen use in pregnancy tests. These antibodies will not interfere

with urine assays, however, as they are not present in urine.

15

S.C.’s home pregnancy test is positive. Because she is pregnant she should be

counseled on the possible fetal effects of any medications or herbal products she may

be taking and advised to see her primary-care provider as soon as possible.

p. 969

p. 970

No comments:

Post a Comment

اكتب تعليق حول الموضوع

mcq general

 

Search This Blog